Anglonordic is the only life science conference in the UK that is exclusively for European investors and R&D companies from the Nordics and the UK to connect with each other. With an established format of panel discussions, parallel technology and biotech investment rooms, plus 1:1 meetings, this 1-day London conference provides exceptional value. Investors with funds attend free-of-charge.
MEET decision makers at leading and upcoming drug discovery and technology companies from the UK and Nordic regions, along with investment firms from throughout Europe
LEARN from major investment firms about the current status of European investment in life science technologies
GAIN insights from experienced life science operators within the Anglo-Nordic space
The Anglonordic Life Science Conference has a “by-invitation-only” policy. The organisers welcome a limited number of service suppliers as sponsors or exhibitors.
The main conference room has a biotech investment focus; the technology room features devices, diagnostics, delivery and development tools. One-to-one meetings take place throughout the day. The Exhibition and quiet area double up for lunch service and refreshments are available all day.
One-to-one partnering meetings are pre-booked using the globally-renowned Meeting Mojo booking platform. Registered delegates can log in now to browse profiles, set their own availability, request meetings, and promote their company to best advantage.
Conference media partner PharmaVentures Insights offers 20 minute filmed interviews at the conference, free of charge. PharmaVentures Insights is a TV series showcasing the best and the latest of the global life science industry. To date, over 500 senior executives from pharmaceutical, biotech and medtech industries have shared their compelling stories with a 15,000 online viewership. There is no cost associated with the interview and the footage will only be released with your approval. You can also share the interview on your marketing platforms at no cost. Contact Matt Royan at email@example.com to secure your 2018 spot or book using the 1:1 partnering system.
Networking begins on May 23rd with an exclusive Reception, free of charge to all registered delegates.
Attendees at this 2018 event include companies from: Denmark, Finland, Netherlands, Norway, Sweden, Spain, UK
Organisations registered to attend include:
Investors: 4BIO Capital, Advent Life Sciences, Albion Capital, Apposite Capital, Arix Bioscience, Arrowfield Capital, Axilium Holding, BioSeed Capital, Capital Cell, Curam Capital Management, Deepbridge Capital, Draper Esprit, European Investment Bank, Hadean Ventures, Industrifonden, Ignite Capital Partners, Inkef Capital, Innovator Capital, IPF Partners, Investor Corporate AS, J&J Venture Investments, Limerston Capital, Medicxi, M-Ventures, National Institute for Health Research, NCL Technology Ventures, NeoMed, New Science Fund, Newable Private Investment, NetScientific, Novo Holdings, Norgine Ventures, o2h ventures, Seventure, SR One, Sunstone Life Science Ventures, Trilantic Europe, UCB Ventures, Wren Capital, Xontogeny. Delegates: Addbutment, Affibody, Albumedix, APIM Therapeutics, Ascesion Pharma, BioPartner UK, Biotech Pharmacon, CatSci, Cell and Gene Therapy Catapult, CLS AB, Diamond, DMnoMore, DNA Script, Ezenze, F-star, Financial Times, Forendo Pharma, Informa, ionctura, Karus Therapeutics, Lavivo AB, LucyJRobertshaw, Lytics AI, Macrophage Pharma, Medherant, MediCase, Medicon Valley Alliance, Methodicare AB, Mind the Byte, Mission Therapeutics, OncoInvent, Oncopeptides AB, One Nucleus, Optimum Strategic Communications, Plaquetec, Pluvia, Pneumagen, Preglem/Gideon Richter, Prophylix, Public Health England, RSP Systems, Sahlgrenska Science Park, Sartar Therapeutics, Scrip Pharma Intelligence, Stratophase, SweCare, Thrombolytic Science, Tummylab AB, Turku Science Park, XOventure GmbH, Yaqrit. Pharma: Abbvie, Almirall, Astellas, BTG International, Eli Lilly, Ferring Pharmaceuticals, Johnson & Johnson Innovation, Merck, Novo Nordisk, Masters Speciality Pharma, Pfizer, Simcere Pharmaceutical Group, Teijin Pharma.
Investors that registered to attend the Anglonordic Life Science Conference in 2017:
4BIO Capital Partners, Advent Life Sciences, Albion Ventures, Angel investor, Animalcare Limited, Arcus Altor Ltd, Arix Bioscience, Belsize Asset Management, BioCity Group Limited, BioSeed Capital ltd, Caldwell Capital Limited, Cambridge Innovation Capital, Capricorn Venture Partners, CBC Investment Group, Certus, Clubb Capital Ltd, Deepbridge Capital, Epidarex Capital, Esperante, European Investment Fund, Ferghana Partners, Fort Rock Capital, GHO Capital, Harbert European Growth Capital, Health Enterprise East, IAG, Ignite Capital Partners, Inc., Industrifonden, Inventages, IP Group PLC, IPF Partners, Johnson & Johnson Innovation, Johnson and Johnson, Lilly, Locate in Limburg vzw, LSP, Medicon SD Ltd, M Ventures, Metellus AG, Molecular Warehouse, MVM Life Science Partners LLP, NeoMed, NetScientific, New Science Global Healthcare Fund, Newstock Capital, NIHR Office for Clinical Research Infrastructure, Norgine Ventures Management Limited, O2h Ventures Limited, Octopus Ventures, Pfizer Limited, Pharmalink AB, Rainbow Seed Fund, Rosetta Capital, Royal Bank of Canada (RBC), Ruffena Capital, SBA Ltd, SEHTA, Seventure, Spencer Stuart, SR One, Stifel, Sunstone Life Science Ventures, Tassi @ Co, Teijin Pharma Limited, Ventac Partners, Wellcome Trust, Wren Capital